Introduction
============

Breast cancer is one of the most common types of malignancy and is a leading cause of death worldwide, accounting for nearly one million new cases diagnosed and half a million deaths annually.[@b1-ott-8-2453] Incidence rates vary widely according to region, being high in developed countries and lower in developing countries.[@b2-ott-8-2453] This type of cancer is obviously a significant public health problem in Saudi Arabia.

Cytochrome P450 (CYP)19A1 encodes the enzyme aromatase, which catalyzes the conversion of the C19 androgens, androstenedione and testosterone, to estrone and estradiol, respectively.[@b3-ott-8-2453],[@b4-ott-8-2453] Specific single nucleotide polymorphisms (SNPs) in the intronic regions of CYP19A1 have been shown to play a role in altering regulation of transcription and/or splicing of CYP19A1, producing different enzyme products with variable enzymatic activity when compared with the normal gene product.[@b5-ott-8-2453],[@b6-ott-8-2453] Studies have identified SNPs in CYP19A1 that are associated with an increased risk of cancer, primarily in European American, North Indian, and Chinese populations.[@b7-ott-8-2453],[@b8-ott-8-2453] Several studies have been done on polymorphisms in the CYP19 gene in an attempt to identify an association between genetic variations and breast cancer risk, but few studies have found such an association. One report suggested that a tetra-nucleotide repeat polymorphism in intron 4 (TTTA)n was strongly associated with the risk of breast cancer.[@b9-ott-8-2453] However, studies of other genetic variations have not shown a clear association with risk of breast cancer, thus generating a situation of inconsistent results.[@b10-ott-8-2453]--[@b13-ott-8-2453] Hence, in the present population-based, case--control study, we investigated the genotype distribution of rs4646 and rs700518 SNPs in patients with breast cancer.

Materials and methods
=====================

Study population
----------------

The study population comprised 148 females (median age 48 years) suffering from breast cancer and attending the outpatient clinics of the clinical co-investigators at King Fahad Medical City Hospital, Riyadh, Saudi Arabia, and 154 age-matched normal healthy controls also attending King Fahad Medical City Hospital for minor illnesses and recruited following physical examinations after exclusion of a breast cancer diagnosis and history of cancer or cancer-related diseases. The patients and controls were of Saudi Arabian ethnicity. Demographic data, age at diagnosis, tumor grade, and immunohistochemical determination of estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor status were recorded. The study was approved by the institutional review board of King Khalid University Hospital. Written informed consent was obtained from all participants.

Genotyping
----------

Genomic DNA was extracted from blood samples taken from breast cancer cases and controls using a QIAmp DNA blood mini kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. The rs1130409 SNP in the APE1 gene was genotyped using the TaqMan allelic discrimination assay as described previously.[@b14-ott-8-2453] Ten percent of the samples were subjected to repeated analysis for verification of the genotyping procedures.[@b15-ott-8-2453]

Statistical analysis
--------------------

Genotype and allelic frequencies were compared using Fisher's Exact test (two-tailed) as described by Alanazi et al[@b15-ott-8-2453] to describe the *χ*^2^ test and odds ratios, and 95% confidence intervals to know the variation between cancer cases and controls. The statistical analysis was performed using Statistical Package for the Social Sciences version 21.0 (SPSS Inc, Chicago, IL).[@b16-ott-8-2453]

Results
=======

One hundred and forty-eight breast cancer cases and 154 healthy controls were included in this study. The clinical characteristics of the breast cancer cases and the healthy controls are given in [Table 1](#t1-ott-8-2453){ref-type="table"}. Of 148 confirmed cases of breast cancer, 67 were ER-positive, 78 were ER-negative, 89 were PR-positive, 59 were PR-negative, 57 were HER2-positive, and 89 were HER2-negative.

All the genotypic distributions were consistent with that expected in the Hardy--Weinberg model. The homozygous wild-type allele was used as a reference to calculate the odds of acquiring breast cancer in comparison with the other two genotypes. The genotype frequencies of the analyzed SNPs along with the resulting odds ratio and significance levels are shown in [Table 1](#t1-ott-8-2453){ref-type="table"}. We did not find any significant association between the two SNPs and risk of breast cancer.

In the present study, we found no association with CYP19A1 rs4646 and rs700518 genotypes between breast cancer cases and matched healthy controls. The frequencies of rs4646 (A \> C) genotypes in breast cancer cases were 8 (0.05), 46 (0.31), and 94 (0.64), respectively, whereas in healthy controls the frequencies were 8 (0.05), 47 (0.30), and 99 (0.65), respectively. Breast cancer patients did not show any risk when compared with healthy individuals ([Table 1](#t1-ott-8-2453){ref-type="table"}). As shown in [Table 1](#t1-ott-8-2453){ref-type="table"}, the frequency of the rs700518, (A \> G) A/A, A/G, and G/G genotypes were 60 (0.41), 66 (0.45), and 22 (0.15), respectively, in breast cancer patients and 55 (0. 36), 71 (0.46), and 28 (0.18), respectively, in controls. Breast cancer patients did not show any risk when compared with healthy individuals ([Table 1](#t1-ott-8-2453){ref-type="table"}).

The correlation between CYP19A1 rs4646 and rs700518 SNP status and clinicopathological characteristics was also analyzed, but interestingly none of these parameters showed an association with breast cancer in this Saudi population. Breast cancer patients did not show any association between age and ER-positive, ER-negative, PR-positive, HER2-positive, and HER2-negative status ([Tables 2](#t2-ott-8-2453){ref-type="table"}[](#t3-ott-8-2453){ref-type="table"}[](#t4-ott-8-2453){ref-type="table"}--[5](#t5-ott-8-2453){ref-type="table"}).

We also generated a regional linkage disequilibrium (LD) plot using SNAP (SNP Annotation and Proxy Search, <http://www.broadinstitute.org/mpg/snap/ldplot.php>) for CYP19A1 rs4646 and rs700518. The LD plot indicated that there are multiple loci near rs4646 and rs700518 with high LD (*r*^2^\>0.8), which suggests that fine mapping is necessary to evaluate the genetic effect of CYP19A1 on cancer as well as functional studies ([Figures 1](#f1-ott-8-2453){ref-type="fig"} and [2](#f2-ott-8-2453){ref-type="fig"}).

Discussion
==========

Numerous genetic variations of CYP19A1 have been reported, even though the possible functional significance of most of these polymorphisms is still undefined. Various studies conducted in specific breast cancer populations have analyzed a few common CYP19A1 polymorphisms and generated inconsistent results with regard to their possible association with cancer risk, sex hormone levels, HER2 status, and survival.[@b9-ott-8-2453],[@b17-ott-8-2453]--[@b20-ott-8-2453] In the present study, our data do not support any appreciable association between CYP19A1 rs4646 and rs700518 genotypes and breast cancer risk in the Saudi population ([Table 1](#t1-ott-8-2453){ref-type="table"}). We analyzed the association of both these SNPs with various clinical parameters and found no evidence of heterogeneity for either rs4646 or rs700518 in Saudi breast cancer patients, and found no association except with rs4646 in PR-negative patients ([Tables 2](#t2-ott-8-2453){ref-type="table"}[](#t3-ott-8-2453){ref-type="table"}[](#t4-ott-8-2453){ref-type="table"}--[5](#t5-ott-8-2453){ref-type="table"}).

Some strengths and limitations of our study should be noted. Its strengths include the population-based and prospective study design in the central region of Saudi Arabia, thereby minimizing selection bias, and the detailed review of the cancer diagnosis, thereby minimizing disease mis-classification. However, our nested case--control sample was relatively small in size, which hampered our ability to evaluate specific gene-disease association. Confirmation of our findings in larger populations of women of different ethnicities could provide evidence for the role of the CYP19A1 gene in breast carcinoma.
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###### 

Genotype frequencies of *Aromatase* gene polymorphism in breast cancer cases and controls

  SNP          Variant      Cases        Controls    OR             CI             *χ*^2^ value   *P*-value
  ------------ ------------ ------------ ----------- -------------- -------------- -------------- -----------
  rs4646       AA           8 (0.05)     8 (0.05)    Ref                                          
  AC           46 (0.31)    47 (0.31)    0.979       0.339--2.828   0.002          0.96831        
  CC           94 (0.64)    99 (0.64)    0.949       0.350--2.625   0.01           0.93490        
  AC + CC      140 (0.95)   146 (0.95)   0.959       0.350--2.625   0.01           0.93490        
  A            62 (0.20)    63 (0.20)    Ref                                                      
  C            234 (0.80)   245 (0.80)   0.971       0.655--1.439   0.02           0.88154        
  rs700518     AA           60 (0.41)    55 (0.36)   Ref                                          
  Val \> Val   AG           66 (0.45)    71 (0.46)   0.852          0.519--1.400   0.40           0.52715
  GG           22 (0.15)    28 (0.18)    0.720       0.369--1.404   0.93           0.33451        
  AG + GG      88 (0.59)    99 (0.64)    0.815       0.512--1.297   0.75           0.38789        
  A            186 (0.63)   181 (0.59)   Ref                                                      
  G            110 (0.37)   127 (0.41)   0.843       0.608--1.169   1.05           0.30561        

**Abbreviations:** CI, confidence interval; OR, odds ratio; Ref, reference; SNP, single nuclear polymorphism.

###### 

Genotype frequencies of *Aromatase* gene polymorphism in breast cancer cases (above 48 years old versus below 48 years old)

  SNP          Variant      Cases          Controls    OR             CI     *χ*^2^ value   *P*-value
  ------------ ------------ -------------- ----------- -------------- ------ -------------- -----------
  rs4646                    **Above 48**                                                    
  AA           4 (0.06)     1 (0.01)       Ref                                              
  AC           21 (0.30)    20 (0.29)      0.263       0.027--2.554   1.49   0.22256        
  CC           45 (0.64)    47 (0.69)      0.239       0.026--2.224   1.83   0.17573        
  AC + CC      66 (0.94)    67 (0.99)      0.246       0.027--2.262   1.78   0.18228        
  AA           29 (0.21)    22 (0.16)      Ref                                              
  CC           111 (0.79)   114 (0.84)     0.739       0.400--1.363   0.94   0.33150        
  rs4646                    **Below 48**                                                    
  AA           4 (0.49)     7 (0.08)       Ref                                              
  AC           25 (0.44)    27 (0.31)      1.620       0.423--6.210   0.50   0.47887        
  CC           49 (0.07)    52 (0.60)      1.649       0.454--5.984   0.59   0.44337        
  AC + CC      74 (0.51)    79 (0.92)      1.639       0.461--5.830   0.58   0.44136        
  AA           33 (0.71)    41 (0.24)      Ref                                              
  CC           123 (0.29)   131 (0.76)     1.167       0.693--1.963   0.34   0.56148        
  rs700518                  **Above 48**                                                    
  Val \> Val   AA           34 (0.33)      24 (0.35)   Ref                                  
  AG           31 (0.45)    36 (0.53)      0.608       0.299--1.236   1.90   0.16804        
  GG           5 (0.22)     8 (0.12)       0.441       0.129--1.515   1.74   0.18673        
  AG + GG      36 (0.67)    44 (0.65)      0.578       0.292--1.144   2.50   0.11416        
  AA           99 (0.56)    84 (0.62)      Ref                                              
  GG           41 (0.44)    52 (0.38)      0.669       0.405--1.105   2.47   0.11581        
  rs700518                  **Below 48**                                                    
  Val \> Val   AA           26 (0.0)       31 (0.36)   Ref                                  
  AG           35 (0.0)     39 (0.45)      1.070       0.535--2.139   0.04   0.84815        
  GG           17 (0.0)     16 (0.19)      1.267       0.537--2.990   0.29   0.58913        
  AG + GG      52 (0.0)     55 (0.64)      1.127       0.592--2.148   0.13   0.71557        
  AA           87 (0.0)     101 (0.59)     Ref                                              
  GG           69 (0.0)     71 (0.41)      1.128       0.728--1.749   0.29   0.58937        

**Abbreviations:** CI, confidence interval; OR, odds ratio; Ref, reference; SNP, single nuclear polymorphism.

###### 

Genotype frequencies of *Aromatase* gene polymorphism in breast cancer cases (ER-positive versus ER-negative)

  SNP          Variant      Cases                 Controls    OR             CI      *χ*^2^ value   *P*-value
  ------------ ------------ --------------------- ----------- -------------- ------- -------------- -----------
  rs4646                    **ER-positive**                                                         
  AA           2 (0.03)     8 (0.05)              Ref                                               
  AC           18 (0.27)    47 (0.31)             1.532       0.297--7.913   0.26    0.60859        
  CC           47 (0.70)    99 (0.64)             1.899       0.388--9.293   0.65    0.42165        
  AC + CC      65 (0.97)    146 (0.95)            1.781       0.368--8.618   0.53    0.46758        
  AA           22 (0.16)    63 (0.20)             Ref                                               
  CC           112 (0.84)   245 (0.80)            1.309       0.767--2.234   0.98    0.32231        
  rs4646                    **ER-negative**                                                         
  AA           6 (0.08)     8 (0.05)              Ref                                               
  AC           26 (0.33)    47 (0.31)             0.738       0.231--2.357   0.26    0.60680        
  CC           46 (0.59)    99 (0.64)             0.620       0.203--1.889   0.72    0.39647        
  AC + CC      72 (0.92)    146 (0.95)            0.658       0.220--1.966   0.57    0.45044        
  AA           38 (0.24)    63 (0.20)             Ref                                               
  CC           118 (0.76)   245 (0.80)            0.798       0.505--1.263   0.93    0.33564        
  rs700518                  **ER**-**positive**                                                     
  Val \> Val   AA           30 (0.45)             55 (0.36)   Ref                                   
  AG           32 (0.48)    71 (0.46)             0.775       0.418--1.435   0.66    0.41646        
  GG           5 (0.07)     28 (0.18)             0.458       0.179--1.173   2.72    0.09915        
  AG + GG      37 (0.55)    99 (0.64)             0.685       0.382--1.228   1.62    0.20312        
  AA           92 (0.69)    181 (0.59)            Ref                                               
  GG           42 (0.31)    127 (0.41)            0.697       0.455--1.067   2.78    0.09567        
  rs700518                  **ER-negative**                                                         
  Val \> Val   AA           28 (0.36)             55 (0.36)   Ref                                   
  AG           33 (0.42)    71 (0.46)             0.913       0.494--1.688   0.08    0.77148        
  GG           17 (0.22)    28 (0.18)             1.193       0.560--2.538   0.21    0.64739        
  AG + GG      50 (0.64)    99 (0.64)             0.992       0.562--1.751   0.001   0.97807        
  AA           89 (0.57)    181 (0.59)            Ref                                               
  GG           67 (0.43)    127 (0.41)            1.073       0.727--1.584   0.13    0.72348        

**Abbreviations:** CI, confidence interval; ER, estrogen receptor; OR, odds ratio; Ref, reference; SNP, single nuclear polymorphism.

###### 

Genotype frequencies of *Aromatase* gene polymorphism in breast cancer cases (PR-positive versus PR-negative)

  SNP          Variant      Cases             Controls    OR             CI       *χ*^2^ value   *P*-value
  ------------ ------------ ----------------- ----------- -------------- -------- -------------- -----------
  rs4646                    **PR-positive**                                                      
  AA           5 (0.06)     8 (0.05)          Ref                                                
  AC           28 (0.31)    47 (0.31)         0.953       0.284--3.201   0.01     0.93817        
  CC           56 (0.63)    99 (0.64)         0.905       0.282--2.900   0.03     0.86660        
  AC + CC      84 (0.94)    146 (0.95)        0.921       0.292--2.905   0.02     0.88768        
  AA           38 (0.21)    63 (0.20)         Ref                                                
  CC           140 (0.79)   245 (0.80)        0.947       0.602--1.490   0.05     0.81502        
  rs4646                    **PR-negative**                                                      
  AA           3 (0.05)     8 (0.05)          Ref                                                
  AC           18 (0.31)    47 (0.31)         1.021       0.243--4.284   0.0001   0.97704        
  CC           38 (0.64)    99 (0.64)         1.024       0.258--4.063   0.0012   0.97358        
  AC + CC      56 (0.95)    146 (0.95)        1.023       0.262--3.994   0.001    0.97409        
  AA           24 (0.20)    63 (0.20)         Ref                                                
  CC           94 (0.80)    245 (0.80)        1.007       0.595--1.706   0.001    0.97888        
  rs700518                  **PR-positive**                                                      
  Val \> Val   AA           39 (0.44)         55 (0.36)   Ref                                    
  AG           38 (0.43)    71 (0.46)         0.755       0.427--1.333   0.94     0.33189        
  GG           12 (0.13)    28 (0.18)         0.604       0.274--1.333   1.57     0.21003        
  AG + GG      50 (0.66)    99 (0.64)         0.712       0.418--1.214   1.56     0.21131        
  AA           116 (0.65)   181 (0.59)        Ref                                                
  GG           62 (0.35)    127 (0.41)        0.762       0.519--1.117   1.95     0.16306        
  rs700518                  **PR-negative**                                                      
  Val \> Val   AA           21 (0.36)         55 (0.36)   Ref                                    
  AG           28 (0.47)    71 (0.46)         1.033       0.530--2.011   0.01     0.92423        
  GG           10 (0.17)    28 (0.18)         0.935       0.388--2.255   0.02     0.88168        
  AG + GG      38 (0.64)    99 (0.64)         1.005       0.537--1.881   0.0012   0.98683        
  AA           70 (0.59)    181 (0.59)        Ref                                                
  GG           48 (0.41)    127 (0.41)        0.977       0.635--1.505   0.01     0.91689        

**Abbreviations:** CI, confidence interval; PR, progesterone receptor; OR, odds ratio; Ref, reference; SNP, single nuclear polymorphism.

###### 

Genotype frequencies of *Aromatase* gene polymorphism in breast cancer cases (HER2-positive versus HER2-negative)

  SNP          Variant      Case                Control     OR             CI       *χ*^2^ value   *P*-value
  ------------ ------------ ------------------- ----------- -------------- -------- -------------- -----------
  rs4646                    **HER2-positive**                                                      
  AA           3 (0.05)     8 (0.05)            Ref                                                
  AC           21 (0.37)    47 (0.31)           1.191       0.287--4.945   0.06     0.80916        
  CC           33 (0.58)    99 (0.64)           0.889       0.223--3.548   0.03     0.86748        
  AC + CC      54 (0.95)    146 (0.95)          0.986       0.252--3.855   0.0001   0.98418        
  AA           27 (0.24)    63 (0.20)           Ref                                                
  CC           87 (0.76)    245 (0.80)          0.829       0.496--1.384   0.52     0.47202        
  rs4646                    **HER2-negative**                                                      
  AA           4 (0.04)     8 (0.05)            Ref                                                
  AC           25 (0.28)    47 (0.31)           1.064       0.292--3.882   0.01     0.92536        
  CC           60 (0.67)    99 (0.64)           1.212       0.350--4.198   0.09     0.76122        
  AC + CC      85 (0.96)    146 (0.95)          1.164       0.340--3.982   0.06     0.80817        
  AA           33 (0.19)    63 (0.20)           Ref                                                
  CC           145 (0.81)   245 (0.80)          1.130       0.707--1.805   0.26     0.60941        
  rs700518                  **HER2-positive**                                                      
  Val \> Val   AA           24 (0.42)           55 (0.36)   Ref                                    
  AG           25 (0.44)    71 (0.46)           0.807       0.416--1.564   0.40     0.52475        
  GG           8 (0.14)     28 (0.18)           0.655       0.261--1.644   0.82     0.36534        
  AG + GG      33 (0.58)    99 (0.64)           0.764       0.411--1.421   0.73     0.39436        
  AA           73 (0.64)    181 (0.59)          Ref                                                
  GG           41 (0.36)    127 (0.41)          0.800       0.513--1.249   0.96     0.32619        
  rs700518                  **HER2-negative**                                                      
  Val \> Val   AA           35 (0.39)           55 (0.36)   Ref                                    
  AG           41 (0.46)    71 (0.46)           0.907       0.512--1.608   0.11     0.73934        
  GG           13 (0.15)    28 (0.18)           0.730       0.334--1.596   0.63     0.42891        
  AG + GG      54 (0.61)    99 (0.64)           0.857       0.500--1.468   0.32     0.57434        
  AA           111 (0.62)   181 (0.59)          Ref                                                
  GG           67 (0.38)    127 (0.41)          0.860       0.589--1.256   0.61     0.43580        

**Abbreviations:** CI, confidence interval; OR, odds ratio; Ref, reference; SNP, single nuclear polymorphism.
